Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ITK | Q08881 | 2/20 | 0.44 |
| ▸ | PPARG | P37231 | 7/20 | 0.43 |
| ▸ | TRPV1 | Q8NER1 | 1/20 | 0.42 |
| ▸ | DGAT2 | Q96PD7 | 1/20 | 0.41 |
| ▸ | NTRK1 | P04629 | 4/20 | 0.40 |
| ▸ | SLC40A1 | Q9NP59 | 1/20 | 0.40 |
| ▸ | NPC1 | O15118 | 1/20 | 0.40 |
| ▸ | RAB9A | P51151 | 1/20 | 0.40 |
| ▸ | NAMPT | P43490 | 1/20 | 0.39 |
| ▸ | P2RX7 | Q99572 | 1/20 | 0.39 |
| ▸ | GLS | O94925 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14587697 | 0.89 | PPARG (0.46) | PPARGNTRK1NPC1RAB9A | |
| SCHEMBL14301499 | 0.89 | PPARG (0.46) | PPARGNTRK1NPC1RAB9A | |
| SCHEMBL14587622 | 0.88 | EPHX2 (0.44) | PPARGNTRK1NPC1RAB9A | |
| SCHEMBL5010420 | 0.87 | PPARG (0.47) | PPARGP2RX7 | |
| SCHEMBL14587613 | 0.84 | NTRK1 (0.54) | PPARGNTRK1NPC1RAB9A | |
| SCHEMBL14587660 | 0.84 | PPARG (0.43) | PPARGNTRK1SLC40A1NPC1RAB9A | |
| SCHEMBL5008489 | 0.84 | PPARG (0.51) | PPARGNPC1RAB9A | |
| SCHEMBL5012182 | 0.84 | PPARG (0.56) | PPARGNPC1RAB9A | |
| SCHEMBL5013662 | 0.84 | PPARG (0.48) | PPARG | |
| SCHEMBL14587620 | 0.84 | NTRK1 (0.46) | PPARGNTRK1NPC1RAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070032529-A1 | Pyrazole compounds and their use as antidiabetes agents | JAPAN TOBACCO INC. (JP) | 2007-02-08 | — | — | US | disclosed |
| US-20070032529-A1 | Pyrazole compounds and their use as antidiabetes agents | JAPAN TOBACCO INC. (JP) | 2007-02-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070032529-A1 | Pyrazole compounds and their use as antidiabetes agents | PYGL, GYS2, AGL | ITK 2614/4885PPARG 706/4885TRPV1 4723/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.